A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Inclusion Criteria: \[Phase 1 part\] * Subject is defined as having previously untreated de novo AML according to the World Health Organization (WHO) criteria (2008) within 28 days prior to study enrollment. * Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. * Subject must meet all of the following criteria in the laboratory test at screening: * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of ≤ 2.5 × institutional upper limit of normal (ULN) * Total serum bilirubin level of ≤ 1.5 × institutional ULN * Serum creatinine level of ≤ 1.5 × institutional ULN or an estimated glomerular filtration rate (eGFR) of \> 50 mL/min * Subject is suitable for oral administration of ASP2215. * Female subject falls under the following: * Of non-childbearing potential: * ・Post-menopausal (defined as at least 1 year with no menses without a medical reason such as drug administration) at screening, or * ・Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening) * Of childbearing potential: * ・Has a negative result for the pregnancy test at screening, and * ・Agrees to use an appropriate contraception starting at screening and throughout the study period and for 60 days after the final study drug administration * Female subject agrees not to breastfeed starting at screening and throughout the study period and for 60 days after the final study drug administration. * Femal…